Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.

Inclusion Criteria

• •Age ≥ 18 years and ≤75 years.
• •Diagnosis of CML-CP.
• •ECOG performance of 0-2.
• •Adequate end organ function defined as the following: total bilirubin \<1.5xULN, SGPT \<2.5x ULN, creatinine \<1.5x ULN.
• •Resistance and/or intolerance of at least two second-generation TKIs.
• •Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital.